AlzeCure Pharma AB (DE:AC6)
FRANKFURT:AC6
Want to see DE:AC6 full AI Analyst Report?
AC6 Stock Chart & Stats
€0.15
>-€0.01(-7.07%)
At close: 4:00 PM EST
€0.15
>-€0.01(-7.07%)
Day’s Range― - ―
52-Week Range€0.08 - €0.44
Previous CloseN/A
Volume0.00
Average Volume (3M)114.00
Market Cap
€14.59M
Enterprise Value€113.37M
Total Cash (Recent Filing)€50.34M
Total Debt (Recent Filing)€5.12M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding114,914,450
10 Day Avg. Volume0
30 Day Avg. Volume114
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityModest debt and a low debt-to-equity ratio provide structural financial flexibility for an R&D-stage biotech. Lower leverage reduces short-term refinancing pressure and preserves optionality to pursue partnerships or milestone-based deals, extending runway despite recurring cash burn.
Partnership-driven Business ModelA product-lite, partner-focused model is structurally capital-efficient for pre-commercial biotech. By aiming for upfront, milestone and royalty deals, AlzeCure can concentrate R&D resources, avoid building large commercial infrastructure, and capture upside through licensing outcomes over time.
Focused CNS Pipeline And Discovery PlatformConcentrated expertise in small-molecule CNS candidates addresses large, chronic market needs (Alzheimer’s, pain). A platform capable of generating multiple assets increases the chance of partnerable programs and spreads binary development risk, creating durable licensing opportunities.
Bears Say
No Revenue And Widening LossesPersistent lack of product revenue and growing net losses mean long-term value depends entirely on successful clinical progress or partner deals. Continued negative profitability increases execution risk and makes sustaining operations without external financing uncertain over the medium term.
Negative And Inconsistent Cash GenerationTwo consecutive years of negative operating and free cash flow indicate ongoing cash burn and uneven cash generation. This creates structural reliance on equity issuance or licensing receipts to fund R&D, raising dilution risk and potential disruptions to program timelines if financing stalls.
Eroding Equity BaseMaterial decline in equity over several years signals capital erosion from sustained losses. A thinner equity buffer reduces resilience to adverse outcomes, increases sensitivity to further losses, and can weaken negotiating leverage with partners or lenders when seeking non-dilutive or favorable financing.
AC6 FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was €0.08 and its highest was €0.44 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is €14.59M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is May 05, 2026 which is in 4 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on Feb 26, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.014.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 114,914,450 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -€0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.667%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in DE:AC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.